OBJECTIVE: To probe into the efficacy and safety of cyclophosphamide in treatment of myasthenia gravis in children with thymus adenoma of different malignant degree. METHODS: Totally 84 cases of myasthenia gravis in children with thymus adenoma of different malignant degree admitted into Children's Hospital Affiliated to Zhengzhou University from Jan. 2010 to Jan.2018 were extracted as the research objects. Children with myasthenia gravis with low malignant degree of thymoma were included as the control group (n=42), and children with myasthenia gravis with high malignant degree of thymoma were included as the observation group (n=42). Both groups were treated with cyclophosphamide. The clinical absolute scores of myasthenia gravis, clinical efficacy and the incidence of adverse drug reactions were compared between two groups. RESULTS: After treatment, the absolute clinical scores of myasthenia gravis in the observation group and the control group were (7.33±1.04) and (7.28±0.98) points, respectively, which were lower than those before treatment, and the difference was statistically significant (P＜0.05), but the difference between the two groups was not statistically significant (P＞0.05). The total effective rate in the observation group was 85.71％ (36/42), significantly higher than that in the control group (64.29％, 27/42), with statistically significant difference (P＜0.05). During the treatment, the incidence of adverse drug reactions in the observation group and the control group were 11.90％ (5/42) and 9.52％ (4/42), respectively, with statistically significant differences (P＞0.05). CONCLUSIONS: Cyclophosphamide is more effective in treatment of myasthenia gravis in children with thymus adenoma of higher malignant degree, and the safety is higher.%目的:探讨环磷酰胺治疗儿童重症肌无力伴不同恶性程度胸腺瘤的疗效及安全性.方法:回顾性选取2010年1月至2018年1月郑州大学附属儿童医院收治的重症肌无力伴恶性胸腺瘤患儿84例, 将重症肌无力伴恶性程度较低的胸腺瘤患儿纳为对照组 (42例), 将重症肌无力伴恶性程度较高的胸腺瘤患儿纳为观察组 (42例).两组患儿均采用环磷酰胺治疗.比较两组患儿重症肌无力临床绝对评分、临床疗效及治疗期间不良反应发生情况的差异.结果:治疗后, 观察组、对照组患儿重症肌无力临床绝对评分分别为 (7.33±1.04) 、 (7.28±0.98) 分, 均较治疗前明显降低, 差异有统计学意义 (P＜0.05), 但组间比较的差异无统计学意义 (P＞0.05).观察组患儿的总有效率为85.71％ (36/42), 明显高于对照组的64.29％ (27/42), 差异有统计学意义 (P＜0.05).治疗期间, 观察组、对照组患儿的不良反应发生率分别为11.90％ (5/42) 、9.52％ (4/42), 差异无统计学意义 (P＞0.05).结论:环磷酰胺治疗儿童重症肌无力伴恶性程度较高的胸腺瘤的疗效更为显著, 且安全性较高.
展开▼
